Related Experiment Video
Updated: Jul 19, 2026
Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
Published on: July 30, 2016
Luteolin prevents TNF-α-induced NF-κB activation and ROS production in cultured human placental explants and
Adrian C Eddy1, Augustine Rajakumar2, Frank T Spradley3
1Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Chicago, IL, USA.
Insights
Luteolin, a bioflavonoid, effectively reduces inflammation and oxidative stress implicated in preeclampsia (PE). This compound shows promise as a potential therapeutic for PE, a serious pregnancy disorder.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Cell Biology
Background:
- Preeclampsia (PE) is a major cause of maternal and perinatal mortality with no approved treatments.
- PE pathophysiology involves inflammation, oxidative stress, and angiogenic imbalance.
- Luteolin is a known inhibitor of soluble fms-like tyrosine kinase 1 (sFlt-1), a factor implicated in PE.
Purpose of the Study:
- To investigate luteolin's potential to reduce inflammation and oxidative stress in preeclampsia.
- To determine if luteolin affects key pathways involved in PE development.
Main Methods:
- Human placental explants and endothelial cells were stimulated with tumor necrosis factor-alpha (TNF-α).
- Luteolin's effects on NF-κB activation, reactive oxygen species (ROS), interleukin-6 (IL-6), and endothelin-1 (ET-1) were measured.
- Techniques included ELISA and fluorescence microscopy.
Main Results:
- Luteolin significantly reduced NF-κB activation, ROS, and IL-6 and ET-1 expression in endothelial cells.
- Luteolin also decreased NF-κB phosphorylation in human placental explants.
- These findings indicate luteolin's anti-inflammatory and antioxidant effects relevant to PE.
Conclusions:
- Luteolin inhibits key pathways contributing to preeclampsia development.
- Further research into luteolin as a potential preeclampsia therapeutic is warranted.
Introduction:
Preeclampsia (PE) is a serious hypertensive pregnancy disorder and a leading cause of maternal and perinatal morbidity and mortality. Despite the prevalence and complications, there are no approved therapeutics to relieve PE symptoms. Inflammation, oxidative stress, and angiogenic imbalance have been shown to contribute to the PE pathophysiology, though there is a lack of understanding in how best to target these pathways in PE. We recently demonstrated that the bioflavonoid luteolin is a potent inhibitor of the anti-angiogenic and pro-hypertensive soluble fms-like tyrosine kinase 1 (sFlt-1), and here we aimed to determine if luteolin was also capable of reducing inflammation and oxidative stress pathways.
Methods:
Tumor necrosis factor (TNF)-α, which is upregulated in PE, was utilized to stimulate these pathways in human placental explants and endothelial cells. Endothelin-1 (ET-1) and interleukin (IL)-6 in the media from explants and cells were measured via ELISA, and NF-κB localization and reactive oxygen species were detected via fluorescence microscopy.
Results:
Pretreatment with luteolin demonstrated significant reductions in NF-κB activation, reactive oxygen species, superoxide, and IL-6 and ET-1 expression in endothelial cells. We also saw a significant reduction in phosphorylation of NF-κB in human placental explants.
Discussion:
These data demonstrate that luteolin inhibits pathways implicated in the development of PE and should be explored further for its potential as a PE therapeutic.
More Related Videos
12:50Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
11:44A Primary Human Trophoblast Model to Study the Effect of Inflammation Associated with Maternal Obesity on Regulation of Autophagy in the Placenta
Published on: September 27, 2017
